Traws Pharma, Inc. insider trading

TRAWNASDAQ

$0.54-0.03 (-5.26%)as of Oct 5, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 6, 2025 to Oct 5, 2026. Price (-76.0%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Unlock quarterly net flow

Key players

IDIain D. DukesChief Executive Officer1.1135%of company
NSNikolay SavchukChief Operating Officer0.98%of company
CDCharles David PauzaChief Science Officer Virology0.7546%of company
RRRobert RedfieldChief Medical Officer0.7413%of company
WCWerner CautreelsDirector0.7107%of company
CNCharles Nolan ParkerChief Financial Officer0.1002%of company
MTMary Teresa ShoemakerDirector0.0409%of company
JEJack E. StoverDirector0.0401%of company
TCTrafford ClarkeDirector0.0401%of company
JHJohn Harold LeamanDirector0.0264%of company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
TRAW	OrbiMed Capital GP VIII LLC10% Owner	Open market purchase$998K	+98.7%	$1.67	$998K	Apr 16, 2026	Apr 28, 2026

End of history · 1 transactions